Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials Publication Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials Model-based drug development in oncology is still lagging despite a good momentum in the clinical…CertaraApril 1, 2014
Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients with Non-small Cell Lung Cancer Based on MONET1 Study Results Publication Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients with Non-small Cell Lung Cancer Based on MONET1 Study Results The motesanib phase III MONET1 study failed to show improvement in overall survival (OS) in…CertaraApril 1, 2014
Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults Publication Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults Azithromycin's extensive distribution to proinflammatory cells, including peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells…CertaraMarch 5, 2014
Population Pharmacokinetic Analysis of Axitinib in Healthy Volunteers Publication Population Pharmacokinetic Analysis of Axitinib in Healthy Volunteers Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors…CertaraFebruary 21, 2014
Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel Publication Absence of Pharmacokinetic Drug-drug Interaction of Pertuzumab with Trastuzumab and Docetaxel Pertuzumab is a novel antihuman epidermal growth factor receptor 2 (HER2) humanized monoclonal antibody. Combined…CertaraNovember 24, 2013
Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab Publication Prediction of Overall Survival or Progression Free Survival by Disease Control Rate at Week 8 Is Independent of Ethnicity: Western Versus Chinese Patients with First-line Non-small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab Categorizations of best response observed at week 8 of first-line treatment in two studies of…CertaraOctober 22, 2013
Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers Publication Differential Pharmacokinetics of Ganitumab in Patients with Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers Ganitumab is an investigational, fully human monoclonal antibody antagonist of the insulin-like growth factor-1 receptor…CertaraOctober 1, 2013
Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters Publication Exposure-response Analysis of Pertuzumab in HER2-positive Metastatic Breast Cancer: Absence of Effect on QTc Prolongation and Other ECG Parameters The phase III trial of pertuzumab plus trastuzumab plus docetaxel versus placebo plus trastuzumab plus…CertaraSeptember 3, 2013
Biodistribution and Pharmacokinetics of EGFR-targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-bearing Mice Publication Biodistribution and Pharmacokinetics of EGFR-targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-bearing Mice The objective of this study was to evaluate qualitative and quantitative biodistribution of epidermal growth…CertaraMay 6, 2013
A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer Publication A Physiologically-based Pharmacokinetic (PBPK) Approach to Evaluate Pharmacokinetics in Patients with Cancer Potential differences in pharmacokinetics (PK) between healthy subjects and patients with cancer were investigated using…CertaraApril 1, 2013